{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:12:34Z","timestamp":1788495154769,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Consorzio Interuniversitario Nazionale per la Bio-Oncologia"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejca.2019.12.031","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T02:30:06Z","timestamp":1583721006000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events"],"prefix":"10.1016","volume":"128","author":[{"given":"Alessio","family":"Cortellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bersanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zoratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Zeppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Anesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rastelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Tudini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Rita","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-5721","authenticated-orcid":false,"given":"Andrea","family":"De Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Migliorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5313","authenticated-orcid":false,"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Vanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2019.12.031_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11912-019-0814-2","article-title":"Modifiable host factors in melanoma: emerging evidence for obesity, diet, exercise, and the microbiome","volume":"21","author":"Warner","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2019.12.031_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1759-7714.12965","article-title":"Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a \"hypothesis-generator\" preliminary report","volume":"10","author":"Cortellini","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2019.12.031_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2019.12.031_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.031_bib5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.12.031_bib6","doi-asserted-by":"crossref","first-page":"105745","DOI":"10.1016\/j.intimp.2019.105745","article-title":"The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: a pooled analysis of 4090 cancer patients","volume":"74","author":"Xu","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2019.12.031_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2019.12.031_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.12.031_bib9","first-page":"30025","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients","volume":"19","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2019.12.031_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2019.12.031_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2019.12.031_bib12","first-page":"30128","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","volume":"19","author":"Cortellini","year":"2019","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.12.031_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12967-019-02132-x","article-title":"Early fatigue in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: an insight from clinical practice","volume":"17","author":"Cortellini","year":"2019","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.ejca.2019.12.031_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: population-based study","volume":"191","author":"Minana","year":"2014","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ejca.2019.12.031_bib15","first-page":"1150","article-title":"Distinctive features of melanoma and its management in elderly patients: a population-based study in France","volume":"149","author":"Ciocan","year":"2013","journal-title":"JAJA Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2019.12.031_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2015.02.006","article-title":"Treatment of elderly patients with non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology","volume":"16","author":"Gridelli","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2019.12.031_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/0284186X.2015.1115121","article-title":"Trends in Kidney cancer among the elderly in Denmark, 1980-2012","volume":"55","author":"Azawi","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2019.12.031_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2307\/3001775","article-title":"Tests for linear trends in proportions and frequencies","volume":"11","author":"Armitage","year":"1955","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2019.12.031_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some methods for strengthening the common chi-squared tests","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2019.12.031_bib20","series-title":"Applied logistic regression","author":"Hosmer","year":"2013"},{"issue":"4","key":"10.1016\/j.ejca.2019.12.031_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 13","key":"10.1016\/j.ejca.2019.12.031_bib22","doi-asserted-by":"crossref","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients","volume":"10","author":"Remon","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2019.12.031_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.12.031_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1997","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2019.12.031_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2019.12.031_bib26","first-page":"185","article-title":"Asymptomatically efficient rank invariant test procedures","volume":"135","author":"Peto","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.ejca.2019.12.031_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"74","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"issue":"7","key":"10.1016\/j.ejca.2019.12.031_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.12.031_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Investig New Drugs"},{"issue":"7","key":"10.1016\/j.ejca.2019.12.031_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamaoncol.2019.0413","article-title":"PD-1 immune checkpoint inhibitors and immune related adverse events. Understanding the upside of the downside of checkpoint blockade","volume":"5","author":"Davar","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2019.12.031_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.12.031_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.031_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.12.031_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eclinm.2019.03.003","article-title":"Microbiome transplantation and modulation of immune related adverse events","volume":"8","author":"Smibert","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.ejca.2019.12.031_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/imt.15.12","article-title":"Obesity and cancer immunotherapy toxicity","volume":"7","author":"Mirsoian","year":"2015","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.ejca.2019.12.031_bib36","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1084\/jem.20131219","article-title":"Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy","volume":"210","author":"Bouchlaka","year":"2013","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.ejca.2019.12.031_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11912-019-0814-2","article-title":"Modifiable host factors in melanoma: emerging evidence for obesity, diet, exercise, and the microbiome","volume":"21","author":"Warner","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.ejca.2019.12.031_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2019.12.031_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2019.11.003","article-title":"The impact of body composition parameters on severe toxicity of nivolumab","volume":"124","author":"Hirsch","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2019.12.031_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1759-7714.12965","article-title":"Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a \u201chypothesis-generator\u201d preliminary report","volume":"10","author":"Cortellini","year":"2019","journal-title":"Thorac Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2019.12.031_bib41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2019.12.031_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.12.031_bib43","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"The Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:23Z","timestamp":1760732783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":43,"alternative-id":["S0959804920300046"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}